Mosaic Therapeutics Limited
Research and experimental development on biotechnology · London
ActiveUnited KingdomIncorporated 2020Private Limited Company
Financial position
Accounts to 2025-12-31 · GBP · Group accounts
Net assets
£16,662,733
Cash
£7,498,095
Turnover
—
Profit / loss
—
Current assets
£9,573,770
Creditors < 1 year
£1,457,727
Equity
£16,662,733
Average employees
22
Balance-sheet trend
GBP · consolidatedFinancial statements
Selected figures from the best-ranked available filing for each period. Missing values remain unknown.
Some figures were read by AI from scanned accounts, so small errors are possible. View the filed accounts
| Reported figures | 2025-12-3112 months · Group · AI-read | 2024-12-31Group · AI-read | 2020-09-30 |
|---|---|---|---|
| Balance sheet | |||
| Net assets | £16,662,733 | £6,566,713 | £1 |
| Equity | £16,662,733 | £6,566,713 | £1 |
| Share capital | £673 | £302 | — |
| Retained earnings | −£19,786,507 | −£11,044,374 | — |
| Assets | |||
| Fixed assets | £8,546,690 | £394,006 | — |
| Intangible assets | £8,234,269 | — | — |
| Property, plant & equipment | £312,421 | £394,006 | — |
| Current assets | £9,573,770 | £8,105,218 | — |
| Cash at bank | £7,498,095 | £6,417,796 | — |
| Debtors | £2,075,675 | £1,687,422 | — |
| Liabilities | |||
| Creditors within one year | £1,457,727 | £1,932,511 | — |
| Net current assets | £8,116,043 | £6,172,707 | — |
| Assets less current liabilities | £16,662,733 | £6,566,713 | — |
| People & pay | |||
| Average employees | 22 | — | — |
| Source evidence | View filing | View filing | View filing |
From the accounts
What the accounts for 2025-12-31 say about themselves, read by AI from the scanned filing.
- Going concern
- The directors report a material uncertainty about going concern
- Auditor
- PEM Audit Limited · senior statutory auditor Roberta Newman
- Audit opinion
- Clean (unmodified)
- Immediate parent
- Syncona Portfolio Limited · Guernsey
- Ultimate controlling party
- Syncona Limited
- Accounts
- Small company · FRS 102 Section 1A
- Approved
- 2026-08-14, signed by Thomas Fuchs
Subsidiaries (1)
- Mosaic Therapeutics Inc. · 100% · 1521 Concord Pike #201, Wilmington, County of New Castle, 19803
Shares issued in the year (6)
- 6,774,682 Series A2 Preferred Shares · for £68 · 2025-03-10
- 1,303,290 Series A2 Preferred Shares · for £13 · 2025-03-10
- 21,000,000 Series A2 Preferred Shares · for £10,500,000 · 2025-03-28
- 3,000,000 Series A2 Preferred Shares · for £30 · 2025-04-16
- 2,613,938 Series A2 Preferred Shares · for £26 · 2025-10-22
- 599,324 Series A2 Preferred Shares · for £6 · 2025-10-22
Share classes (5)
- 4,230,833 Ordinary Shares of £0.00001 each
- 2,149,659 Growth Shares of £0.00001 each
- 7,333,333 Series A1 Preferred Shares of £0.00001 each
- 50,691,234 Series A2 Preferred Shares of £0.00001 each
- 2,852,223 Deferred Shares of £0.00001 each
Events after the year end (1)
- On 1 May 2026, 130,246 £0.00001 unvested Growth Shares held by ex-employees of the Company were redesignated into 130,246 £0.00001 Deferred Shares.
Secured borrowing
Registered charges, lenders and security interests.
Charges and related records
0 outstanding chargesPhoenix signals
Companies sharing directors across a closure — possible restarts
Azeria Therapeutics Limited
52%formed sharing 1 director with this insolvent company · 134 days apart · 76% name match
No charges available in our records.